Cullinan offers a cash-backed, catalyst-rich biotech opportunity where zipalertinib’s potential launch and CLN-978’s autoimmune optionality create highly asymmetric upside, balanced by significant clinical, regulatory, and dilution risk.
Overview
Cullinan Therapeutics is a clinical-stage biotech pursuing targeted oncology and autoimmune therapies through a lean, asset-centric model. It has no approved products or product revenue, but its pipeline includes zipalertinib for EGFR exon 20 NSCLC, CLN-978 for autoimmune B-cell depletion, velinotamig for lupus nephritis, and CLN-049 for AML. The near-term value driver is zipalertinib’s Taiho-partnered commercialization path, while CLN-978 offers substantial upside as a subcutaneous, off-the-shelf alternative to CAR-T approaches in autoimmune disease.